Last reviewed · How we verify
NCT06260410: LUTRAC
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
trial testing Blood draw for ctDNA and circulating tumor cell collection. in Prostate Cancer Metastatic in 150 participants. Currently enrolling.
1 February 2027
Quick facts
| Lead sponsor | Erasmus Medical Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 20 February 2024 |
| Primary completion | 1 February 2027 |
| Estimated completion | 1 February 2027 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Blood draw for ctDNA and circulating tumor cell collection.
Conditions studied
- Prostate Cancer Metastatic — all drugs for Prostate Cancer Metastatic →
Sponsor
Erasmus Medical Center
Who can join
18 and older, male only, with Prostate Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06260410
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer Metastatic
Currently open trials in the same condition.
- NCT07292168 — A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Ex · Phase 1, PHASE2 · recruiting
- NCT06165302 — Exercise in Prostate Cancer · NA · recruiting
- NCT07484971 — Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria · recruiting
- NCT06972628 — Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 · Phase 2 · recruiting
- NCT07089550 — PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN) · recruiting
Other Erasmus Medical Center trials
Trials by the same sponsor.
- NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
- NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
- NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
- NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
- NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06260410 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
- Last refreshed: 22 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06260410.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing